Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find and typically needed on an urgent basis. The goal of this program is to provide high-quality compounded medications from an Imprimis FDA-inspected facility and ship it within 24-48 hours. Imprimis intends to make this program available in all 50 US states.
"Recent changes in ophthalmic compounding has made it such a challenge to access critical compounded medications, especially for infectious keratitis, where urgent care is essential," stated Marjan Farid, MD, Director of Cornea, Cataract, and Refractive Surgery, Vice-Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine. "Having a trusted partner pharmacy such as Imprimis that puts the patient first and provides timely and cost-efficient medications is so valuable to the ophthalmic community."
Imprimis CEO, Mark L. Baum stated, "The mission of our company is to make innovative medications accessible and affordable for patients. Over the past year, a growing number of our customers have made us aware of their inability to access sight saving medications that are needed on an emergent basis. As a partner to thousands of eye care professionals and in furtherance of our corporate mission, we are pleased to now make these critical medications available."
Physicians can order custom compounded formulations on an as needed basis for their patients. To order a custom compound, please click here to download our order form.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to making high quality innovative medications accessible and affordable in all 50 states. The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or spin-out companies. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is FDA-approved. Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.
View original content with multimedia: http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-announces-program-for-custom-compounded-ophthalmic-formulations-300608524.html
SOURCE Imprimis Pharmaceuticals, Inc.